AstraZeneca revises down efficacy rate of US Covid-19 vaccine trial
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
Full Article
AstraZeneca revises down efficacy rate of US Covid-19 vaccine trial
Upworthy
0 shares
1 views
You might like
Related news coverage
The United Nations In The Fight Against Covid – Analysis
Eurasia Review
The nature of the global Covid pandemic cries out for a multilateral intergovernmental resolution. Yet so far nothing has been..
-
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
Motley Fool
-
Businessinsider.co.za | AstraZeneca revises down its vaccine efficacy in a huge US trial - from 79% to 76%
News24
-
Vial flaws deal fresh blow to Hong Kong vaccinations
MENAFN.com
-
AstraZeneca revises down its vaccine efficacy in a huge US trial, from 79% to 76%, following concerns from Fauci and other experts that the results were outdated
Business Insider
Advertisement
More coverage
AstraZeneca COVID-19 vaccine shows 76% efficacy against symptomatic infection in updated data
Upworthy
AstraZeneca on Thursday published an updated analysis confirming that a Phase 3 trial involving its COVID-19 vaccine was safe..
-
Covid vaccine: AstraZeneca updates US vaccine efficacy results
BBC News
-
Covid vaccine: AstraZeneca amends US vaccine efficacy results
BBC News
-
AstraZeneca says COVID-19 vaccine shows 76% efficacy in updated analysis of U.S. trial
CBC.ca
-
News24.com | AstraZeneca lowers vaccine efficacy to 76% in updated US trial data
News24